Isa-Kd in relapsed/refractory multiple myeloma (RRMM): beyond controlled clinical trials – a detailed real-world analysis
Multiple myeloma (MM) is an incurable hematologic malignancy in which patients with relapsed or refractory disease continue to experience poor outcomes despite recent therapeutic advances. The combination of isatuximab, carfilzomib, and dexamethasone (Isa-Kd) demonstrated significant clinical benefit in the phase 3 IKEMA trial; however, real-world evidence remains limited. This multicenter retrospective study evaluated the effectiveness and safety of Isa-Kd in 89 patients with relapsed or refractory MM (RRMM) treated in routine clinical practice. The median age was 61 years, and most patients received Isa-Kd as second-line therapy (77.5%). High-risk clinical features were frequent, including renal impairment, extramedullary disease, refractoriness to lenalidomide (88.6%) and bortezomib (42.7%), and prior exposure to daratumumab. The overall response rate was 83.8%, with 69.8% of patients achieving a very good partial response (VGPR) or better (≥ VGPR). Median progression-free survival (PFS) and overall survival were not reached, while the restricted mean PFS was 23.8 months. Achieving ≥VGPR was independently associated with improved PFS, whereas high-risk clinical features were not significantly associated with inferior PFS. Toxicity was manageable and consistent with previously reported studies. In conclusion, Isa-Kd demonstrated substantial clinical activity and a manageable safety profile in a real-world RRMM population, including patients with adverse clinical characteristics frequently underrepresented in clinical trials. These findings support Isa-Kd as an effective and well-tolerated treatment option in routine clinical practice, including for patient profiles typically excluded from clinical trials.
Authors
- Ester Clavero (ORCID: https://orcid.org/0000-0001-8585-8273)
- M. Carmen Galán (ORCID: https://orcid.org/0000-0001-7307-2871)
- María Casanova (ORCID: https://orcid.org/0000-0003-0784-7688)
- Sebastián Garzón (ORCID: https://orcid.org/0000-0002-8746-1891)
- Ricarda García‐Sánchez
- M. Jiménez
- Magdalena Alcalá
- Isabel García-Cabrera
- Rocío Fe
- Miguel A. Álvarez
Institutions
- Hospital Costa del Sol (ES)
- Hospital Regional Universitario de Málaga (ES)
- Hospital Universitario Virgen de las Nieves (ES)
- Hospital Universitario Reina Sofía (ES)
- Hospital Clínico Universitario Virgen de la Victoria (ES)
- Hospital Universitario de Jerez (ES)
Publication Details
- Journal
- Annals of Hematology
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1007/s00277-026-07369-3
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00